Tech Company Financing Transactions

CalciMedica Funding Round

CalciMedica, based in La Jolla, secured $21 million from Global Health Sciences Fund, Quark Venture and Sanderling Ventures.

Transaction Overview

Company Name
Announced On
3/12/2021
Transaction Type
Venture Equity
Amount
$21,000,000
Round
Series D
Investors

Global Health Sciences Fund (Lead Investor)

Quark Venture (Lead Investor) (Karimah Es Sabar)

Sanderling Ventures

Valence Life Sciences (Eric Roberts)

Proceeds Purpose
Proceeds from the financing will support the clinical development of CalciMedica's portfolio of CRAC channel inhibitors including Auxora which is being evaluated in an ongoing blinded placebo-controlled clinical trial in severe and critical COVID-19 pneumonia, with over 200 patients randomized to date, and in a Phase 2b trial in acute pancreatitis that will start enrolling patients in the coming weeks.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
505 Coast Blvd S. 202
La Jolla, CA 92037
USA
Email Address
Overview
CalciMedica is engaged in the discovery and development of small molecule drugs for the treatment of inflammatory and autoimmune disorders.
Profile
CalciMedica LinkedIn Company Profile
Social Media
CalciMedica Company Twitter Account
Company News
CalciMedica News
Facebook
CalciMedica on Facebook
YouTube
CalciMedica on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Rachel Leheny
  Rachel Leheny LinkedIn Profile  Rachel Leheny Twitter Account  Rachel Leheny News  Rachel Leheny on Facebook
Chief Financial Officer
Daniel Geffken
  Daniel Geffken LinkedIn Profile  Daniel Geffken Twitter Account  Daniel Geffken News  Daniel Geffken on Facebook
Chief Medical Officer
Sudarshan Hebbar
  Sudarshan Hebbar LinkedIn Profile  Sudarshan Hebbar Twitter Account  Sudarshan Hebbar News  Sudarshan Hebbar on Facebook
Chief Operating Officer
Michael Dunn
  Michael Dunn LinkedIn Profile  Michael Dunn Twitter Account  Michael Dunn News  Michael Dunn on Facebook
Chief Scientific Officer
Kenneth Stauderman
  Kenneth Stauderman LinkedIn Profile  Kenneth Stauderman Twitter Account  Kenneth Stauderman News  Kenneth Stauderman on Facebook
VP - General Counsel
John Dunn
  John Dunn LinkedIn Profile  John Dunn Twitter Account  John Dunn News  John Dunn on Facebook


 

 

Browse more venture capital transactions:

Prev: 3/12/2021: Hugging Face venture capital transaction
Next: 3/12/2021: ixlayer venture capital transaction

 

Share this article

 


News on VC Transactions

We do our best to report on tech company VC transactions. VC investment data records reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary